The efficacy of clopidogrel in preventing recurrent cardiovascular events among Arab population carrying different CYP2C19 mutations: systematic review and meta-analysis

The efficacy of clopidogrel in preventing recurrent cardiovascular events among Arab population carrying different CYP2C19 mutations: systematic review and meta-analysis

Abstract Background The prevalence and the role of CYP2C19 gene mutations concerning recurrent Cardiovascular Events (CVEs) among patients treated with clopidogrel is still controversial especially among Arab people. Therefore, this review aimed to determine the frequency of CYP2C19 polymorphic alle...

Full description

Bibliographic Details
Main Authors:	Abdullah N. Alkattan, Nashwa M. Radwan, Nagla E. Mahmoud, Amjad F. Alfaleh, Amal H. Alfaifi, Khaled I. Alabdulkareem
Format:	Article
Language:	English
Published:	SpringerOpen 2022-06-01
Series:	Egyptian Journal of Medical Human Genetics
Subjects:	CYP2C19 genotypes Pharmacogenetics Clopidogrel Arab population Platelet reactivity Cardiovascular events
Online Access:	https://doi.org/10.1186/s43042-022-00313-w

Similar Items

CYP2C19 genetic variation and individualized clopidogrel prescription in a cardiology clinic
by: Seyed abbas Mirabbasi, et al.
Published: (2017-07-01)

Prevalence of CYP2C19*2 and CYP2C19*3 Allelic Variants and Clopidogrel Use in Patients with Cardiovascular Disease in Trinidad & Tobago
by: Daniele Jones, et al.
Published: (2024-01-01)

A Pharmacogenetic Study of <i>CYP2C19</i> in Acute Coronary Syndrome Patients of Colombian Origin Reveals New Polymorphisms Potentially Related to Clopidogrel Therapy
by: Mariana Angulo-Aguado, et al.
Published: (2021-05-01)

CYP2C19 Genotype‐Guided Antiplatelet Therapy After Percutaneous Coronary Intervention in Diverse Clinical Settings
by: Amber L. Beitelshees, et al.
Published: (2022-02-01)

Differential Impact of Cytochrome 2C19 Allelic Variants on Three Different Platelet Function Tests in Clopidogrel-Treated Patients
by: Renske H. Olie, et al.
Published: (2021-09-01)

Pharmacokinetic, pharmacodynamic, and pharmacogenetic assays to monitor clopidogrel therapy
by: Bhawani Yasassri Alvitigala, et al.
Published: (2020-12-01)

THE SIGNIFICANCE OF PHARMACOGENETIC CYP2C19 TESTING FOR PERSONALIZATION OF THE ANTIPLATELET THERAPY IN CARDIOLOGY PRACTICE
by: K. B. Mirzaev, et al.
Published: (2015-09-01)

Influence of CYP2C19*2 gene variant on therapeutic response during clopidogrel treatment in patients with carotid artery stenosis
by: Bačković Dragana, et al.
Published: (2016-01-01)

Pharmacogenomics in the United States Community Pharmacy Setting: The Clopidogrel-CYP2C19 Example
by: Kisor DF, et al.
Published: (2021-05-01)

CYP2C19 Polymorphism in Ischemic Heart Disease Patients Taking Clopidogrel After Percutaneous Coronary Intervention in Egypt
by: Ahmed Shawky, et al.
Published: (2023-05-01)

CLOPIDOGREL PHARMACOGENETICS
by: A. N. Meshkov
Published: (2016-01-01)

Risk factors for adverse drug reactions associated with clopidogrel therapy
by: Mugosa Snezana, et al.
Published: (2022-04-01)

Practice of CYP450 genotyping and phenotyping in children in a real-life setting
by: Frédérique Rodieux, et al.
Published: (2023-02-01)

Co-Existence of CYP2C19*1/*2 and ABCB1c.3435 CT Genotype has a Potential Impact on Clinical Outcome in CAD Patients Treated with Clopidogrel
by: Nestorovska KA, et al.
Published: (2024-03-01)

Effect of <em>CYP3A4</em>*22 and <em>PPAR-α</em> Genetic Variants on Platelet Reactivity in Patients Treated with Clopidogrel and Lipid-Lowering Drugs Undergoing Elective Percutaneous Coronary Intervention
by: Thomas O. Bergmeijer, et al.
Published: (2020-09-01)

Cytochrome P-450 CYP2C19 genetic polymorphism and its relation with clopidogrel resistance
by: Usman Nawaz, et al.
Published: (2023-11-01)

INFLUENCE OF THE CYP3A4 ISOENZYME METABOLIC ACTIVITY AND CYP2C19 GENE POLYMORPHISMS ON CLOPIDOGREL ANTIPLATELET EFFECT IN PATIENTS WITH ACUTE CORONARY SYNDROME UNDERGOING PERCUTANEOUS CORONARY INTERVENTION
by: K. B. Mirzaev, et al.
Published: (2015-09-01)

The effect of doubling the dose of clopidogrel on platelet aggregation in patients with clopidogrel resistance
by: John I. Louca, et al.
Published: (2014-09-01)

The polymorphism of cytochrome P450 CYP2C19 and resistance to clopidogrel.
by: C. Simoglou
Published: (2017-03-01)

Ticagrelor is more effective than clopidogrel in carrier of nonfunctional CYP2C19 allele who has diabetes and acute coronary syndrome - case report and literature review
by: Rahel Tekeste, et al.
Published: (2022-04-01)

Platelet reactivity after clopidogrel loading in patients with acute ischemic stroke
by: Yukiko Enomoto, et al.
Published: (2022-08-01)

CYP2C19 gene polymorphism and its impact on the long-term prognosis after myocardial infarction
by: Mariya V. Solodun, et al.
Published: (2022-07-01)

The correlation between CYP2C19 Polymorphisms and recurrent risk in Patients with Ischemic Stroke treated with Clopidogrel in Kurdistan region-Iraq
by: Hind Salim Jardaq, et al.
Published: (2022-12-01)

Pharmacogenetic association study on clopidogrel response in Puerto Rican Hispanics with cardiovascular disease: a novel characterization of a Caribbean population
by: Hernandez-Suarez DF, et al.
Published: (2018-06-01)

Influence of CYP450 Enzymes and ABCB1 Polymorphisms on Clopidogrel Response in Moroccan Patients with Acute Coronary Syndromes
by: Mouhrach I, et al.
Published: (2023-10-01)

CLOPIDOGREL RESPONSE IN ACUTE CORONARY SYNDROME PATIENTS WITH CYP2Y12*2 AND CYP2Y12*3 POLYMORPHISMS
by: R. Rahmatini, et al.
Published: (2018-04-01)

CYP2C19 PHARMACOGENETIC TESTING FOR PERSONALIZATION OF ANTIPLATELET THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME IN ROUTINE CLINICAL PRACTICE
by: A. I. Akhmetova, et al.
Published: (2017-12-01)

Genetic polymorphisms of CYP2B6*6, CYP2C8*3 and CYP2D6*4 in vivax malaria patients from Brazilian Amazon
by: José Pereira de Moura Neto, et al.
Published: (2023-11-01)

Pharmacogenomic Impact of CYP2C19 Variation on Clopidogrel Therapy in Precision Cardiovascular Medicine
by: Sherry-Ann Brown, et al.
Published: (2018-01-01)

Pharmacodynamic effects of a new fixed-dose clopidogrel–aspirin combination compared with separate administration of clopidogrel and aspirin in patients treated with coronary stents: The ACCEL-COMBO trial
by: Jin-Sin Koh, et al.
Published: (2017-02-01)

Clinical Utility of CYP2C19 Genotype-Guided Antiplatelet Therapy in Patients at Risk of Adverse Cardiovascular and Cerebrovascular Events: A Review of Emerging Evidence
by: Gower MN, et al.
Published: (2020-07-01)

TRimetazidine as an Agent to affeCt clopidogrEl Response: The TRACER Study
by: Naveen Seecheran, et al.
Published: (2019-07-01)

The Dynamic Effect of Non-CYP3A4-Metabolized and CYP3A4-Metabolized Statins on Clopidogrel Resistance in Patients With Cerebral Infarction
by: Hong Ting Shi, et al.
Published: (2021-10-01)

Substantiation of a clopidogrel metabolism-associated gene (CYP2C19) variation among healthy individuals
by: Anshu Kumar Yadav, et al.
Published: (2023-09-01)

Clopidogrel use and smoking cessation result in lower coated-platelet levels after stroke
by: Angelia C. Kirkpatrick, et al.
Published: (2020-02-01)

Genetic polymorphism of clopidogrel metabolism related gene CYP2C19 gene in Chinese from Foshan area of Guangdong Province
by: Xiao-wen Yuan, et al.
Published: (2022-12-01)

Antiplatelet Effects of Clopidogrel Vs Aspirin in Virologically Controlled HIV
by: Emanuela Marcantoni, PhD, et al.
Published: (2022-11-01)

Impact of CYP2C19 variants on clinical efficacy of clopidogrel and one-year clinical outcomes in coronary heart patients undergoing percutaneous coronary intervention
by: Hong Sun, et al.
Published: (2016-11-01)

Frecuencia de la variante alélica CYP2D6*6 en una muestra de la población cubana
by: Hilda Roblejo Balbuena, et al.

A PCR-lateral flow assay system based on gold magnetic nanoparticles for CYP2C19 genotyping and its clinical applications
by: Yan Xuhong, et al.
Published: (2019-12-01)